An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib Maintenance Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols

Inclusion Criteria:

1. Previous completion of a carfilzomib study within 90 days prior to first dose of
maintenance study drug.

2. Disease Assessments performed within 14 days prior to first dose of maintenance study
drug.

3. Written informed consent in accordance with federal, local, and institutional
guidelines

4. Females of childbearing potential (FCBP)* must have a negative serum or urine
pregnancy test, with a sensitivity of at least 50 mIU/mL, within 3 days prior to
first dose of maintenance study drug.

5. Subjects must agree to adhere to the study visit schedule and other study
requirements and receive outpatient treatment and laboratory monitoring at the
institution that administers the drug.

Exclusion Criteria:

1. Administration of an intervening chemotherapy between the time of previous
carfilzomib study termination and first dose of maintenance study drug.

2. Pregnant or lactating females

3. Diagnosis of a new malignancy of a different tumor type.